Form 13-F position report

ALLOGENE THERAPEUTICS INC

Reported by Wildcat Capital Management LLC

Company profile Manager portfolio Source filing
ALLO CUSIP 019770106 Manager CIK 0001582384
Latest reported change

Reported 2,920,787 shares, unchanged from the prior quarter.

Reported value 20.2%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 4.0% This manager · Q3 2024
Shares 2,920,787 Quarter-end amount reported
Reported value $8,178,204 Fair value at quarter end
Consecutive quarters held 22 Through Q3 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q3 2026 Unchanged 2,920,787 0 (0.0%) 2.68% $4,673,259 2026-10-28
Q2 2026 Unchanged 2,920,787 0 (0.0%) 2.66% $6,075,237 2026-07-22
Q1 2026 Unchanged 2,920,787 0 (0.0%) 6.71% $7,126,720 2026-05-01
Q4 2025 Unchanged 2,920,787 0 (0.0%) 2.93% $4,001,478 2026-02-03
Q3 2025 Unchanged 2,920,787 0 (0.0%) 2.5% $3,621,776 2025-11-14
Q2 2025 Unchanged 2,920,787 0 (0.0%) 1.85% $3,121,495 2025-07-18
Q1 2025 Unchanged 2,920,787 0 (0.0%) 2.28% $4,264,349 2025-05-02
Q4 2024 Unchanged 2,920,787 0 (0.0%) 2.46% $6,221,276 2025-01-29
Q3 2024 Unchanged 2,920,787 0 (0.0%) 4.0% $8,178,204 2024-11-08
Q2 2024 Added 2,920,787 +1,000,000 (52.1%) 1.67% $6,805,434 2024-08-14
Q1 2024 Unchanged 1,920,787 0 (0.0%) 2.86% $7,877,861 2024-05-14
Q4 2023 Unchanged 1,920,787 0 (0.0%) 2.13% $6,165,726 2024-02-13
Q3 2023 Unchanged 1,920,787 0 (0.0%) 2.45% $6,088,895 2023-11-09
Q2 2023 Unchanged 1,920,787 0 (0.0%) 3.63% $9,546,311 2023-08-11
Q1 2023 Reduced 1,920,787 -207,583 (-9.8%) 3.25% $9,488,688 2023-05-12
Q4 2022 Unchanged 2,128,370 0 (0.0%) 5.11% $13,387,447 2023-02-07
Q3 2022 Unchanged 2,128,370 0 (0.0%) 8.83% $22,986,000 2022-11-08
Q2 2022 Unchanged 2,128,370 0 (0.0%) 8.04% $24,263,000 2022-08-05
Q1 2022 Added 2,128,370 +412,000 (24.0%) 4.96% $19,389,000 2022-05-13
Q4 2021 Unchanged 1,716,370 0 (0.0%) 4.17% $25,608,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

185 managers reported ALLOGENE THERAPEUTICS INC for Q3 2024.

Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Reduced 30,026,956 -1,230,644 < 0.01% $84,075,477 24 qtrs
TPG GP A LLC Unchanged 18,716,306 0 0.89% $52,405,657 12 qtrs
BlackRock Inc New 17,772,745 +17,772,745 < 0.01% $49,763,686 1 qtr
VANGUARD GROUP INC Added 8,327,699 +132,033 < 0.01% $23,317,557 24 qtrs
STATE STREET CORPORATION Reduced 7,013,083 -655,041 < 0.01% $19,636,632 24 qtrs
Capital World Investors Unchanged 6,896,552 0 < 0.01% $19,310,346 2 qtrs
Lynx1 Capital Management LP Added 6,202,374 +3,974,079 6.15% $17,366,647 2 qtrs
PRIMECAP MANAGEMENT CO CA Reduced 5,668,260 -1,966 0.01% $15,871,128 16 qtrs
CITADEL ADVISORS LLC Added 5,039,594 +2,593,091 < 0.01% $14,110,863 24 qtrs
PRICE T ROWE ASSOCIATES INC MD Reduced 4,838,743 -951,799 < 0.01% $13,550,000 24 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2024
Filed
November 08, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
2,920,787
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.